The Impact of <scp>QSP</scp> Modeling on the Design and Optimization of Gene Therapy Approaches

Quantitative Systems Pharmacology (QSP) is increasingly utilized to support the design and translation of gene therapies. This perspective outlines the application of QSP modeling across three domains of gene therapy: mRNA-based therapeutics, adeno-associated virus (AAV) vectors, and genome editing systems. We highlight opportunities for dose optimization, biomarker interpretation, and mechanistic understanding, while addressing current limitations in model generalizability, data sparsity, and translational relevance. Examples include QSP platforms for lipid nanoparticle (LNP)-delivered mRNA, physiologically based pharmacokinetics (PBPK)-informed AAV biodistribution models, and CRISPR-Cas9-based editing systems. These case studies demonstrate QSP's value in de-risking development and personalizing therapies for rare and complex diseases.

Authors

Institutions

Publication Details

Journal
CPT Pharmacometrics & Systems Pharmacology
Published
2025-11-01
DOI
https://doi.org/10.1002/psp4.70131
Citations
1
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Impact of QSP Modeling on the Design and Optimization of Gene Therapy Approaches

Ekram Ahmed Chowdhury, Guy Meno‐Tetang, Noha Rayad
1 citations
CPT Pharmacometrics & Systems Pharmacology
RNA Interference and Gene Delivery
0.81
article

The Impact of QSP Modeling on the Design and Optimization of Gene Therapy Approaches

Ekram Ahmed Chowdhury, Guy Meno‐Tetang, Noha Rayad
article en
1 citations

Abstract

Quantitative Systems Pharmacology (QSP) is increasingly utilized to support the design and translation of gene therapies. This perspective outlines the application of QSP modeling across three domains of gene therapy: mRNA-based therapeutics, adeno-associated virus (AAV) vectors, and genome editing systems. We highlight opportunities for dose optimization, biomarker interpretation, and mechanistic understanding, while addressing current limitations in model generalizability, data sparsity, and translational relevance. Examples include QSP platforms for lipid nanoparticle (LNP)-delivered mRNA, physiologically based pharmacokinetics (PBPK)-informed AAV biodistribution models, and CRISPR-Cas9-based editing systems. These case studies demonstrate QSP's value in de-risking development and personalizing therapies for rare and complex diseases.

CPT Pharmacometrics & Systems PharmacologyVol. 14(11)
AbbVie (United States) (US), AstraZeneca (Poland) (PL), AstraZeneca (Canada) (CA)
Openalex Percentile: Top 21%
RNA Interference and Gene Delivery
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.